{"entity":{"id":"arovella-therapeutics","kind":"company","name":"Arovella Therapeutics","aka":[],"tldr":"Arovella Therapeutics makes ready-made cell therapies from donor immune cells called iNKT cells, engineered to find cancer cells. Its first product, ALA-101, is in an early trial in people with lymphoma or leukaemia that carry the marker CD19.","summary":"Arovella Therapeutics Limited (ASX: ALA) is an Australian company with a physical base at the Jumar Bioincubator in Melbourne. It engineers invariant natural killer T (iNKT) cells from healthy donors to carry a chimeric antigen receptor, giving an allogeneic, off-the-shelf product; the company says iNKT cells can also recognise lipid-bound CD1d through their invariant T cell receptor and kill through the NKG2D pathway. ALA-101 is a CD19-directed CAR-iNKT therapy for CD19-positive B-cell lymphomas and leukaemias, and ALA-105 is a Claudin 18.2-directed CAR-iNKT programme aimed at solid tumours. Its first registered cancer trial, NCT07518329, a phase 1 dose-escalation and expansion study of a single infusion of ALA-101 after fludarabine and cyclophosphamide conditioning at Australian sites, was posted on ClinicalTrials.gov in April 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.arovella.com/"},{"label":"ALA-101 programme page","url":"https://www.arovella.com/ala-101-car19-inkt"},{"label":"ClinicalTrials.gov: phase 1 trial of ALA-101 in CD19-positive lymphoma and leukaemia (NCT07518329)","url":"https://clinicaltrials.gov/study/NCT07518329"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma","leukaemia"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","allogeneic-cell-therapy"],"targets":["cd19","cldn18-2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","CAR-iNKT has no dedicated technology record in OnCo; it is filed under CAR-T and allogeneic cell therapy.","No financing rows recorded: ASX announcements were not read.","Company website read on 29 October 2026."],"hq":"Melbourne","country":"AU","companyType":"cell-therapy","website":"https://www.arovella.com/","ticker":"ASX: ALA","stage":"public","investors":[],"funding":[]},"route":"/companies/arovella-therapeutics/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}]}}